Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women

Valerie Jackson, Javier A. San Martin, Roberta J. Secrest, Michelle McNabb, Sebastian Carranza-Lira, Pedro Figueroa-Casas, César E. Fernandes, Josefina Romaguera

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

OBJECTIVE: The objectives were to evaluate mammographic changes in breast density that are associated with raloxifene or hormone therapy and to compare the safety profiles of the two therapies. STUDY DESIGN: Postmenopausal women older than 60 years who had a bone mineral density T-score of ≤-1 were assigned randomly to receive raloxifene hydrochloride 60 mg/day or continuous-combined hormone therapy that consisted of conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day in a 1-year, open-label study. Radiologists who were blinded to the treatment assignment assessed the mammograms according to the American College of Radiology Breast Image Reporting and Data System breast density categories. Breast density changes were analyzed for treatment differences. RESULTS: After 12 months of treatment, 0.9% of the women who received raloxifene had increased mammographic breast density compared with 27.4% of the women who received continuous-combined hormone therapy (P < .001). In the continuous-combined hormone therapy group, 77% of the women reported breast tenderness at any time during the study, compared to 22% of the women in the raloxifene group. CONCLUSION: In postmenopausal women with low bone mass, raloxifene therapy for 12 months does not increase mammographic breast density, whereas continuous-combined hormone therapy substantially increases breast density in a significant number of women.

Original languageEnglish
Pages (from-to)389-394
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume188
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

Breast
Hormones
Therapeutics
Conjugated (USP) Estrogens
Breast Density
Raloxifene Hydrochloride
Medroxyprogesterone Acetate
Group Psychotherapy
Radiology
Information Systems
Bone Density
Safety
Bone and Bones

Keywords

  • Breast
  • Breast density
  • Breast tenderness
  • Continuous-combined hormone therapy
  • Raloxifene

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women. / Jackson, Valerie; San Martin, Javier A.; Secrest, Roberta J.; McNabb, Michelle; Carranza-Lira, Sebastian; Figueroa-Casas, Pedro; Fernandes, César E.; Romaguera, Josefina.

In: American Journal of Obstetrics and Gynecology, Vol. 188, No. 2, 01.02.2003, p. 389-394.

Research output: Contribution to journalArticle

Jackson, Valerie ; San Martin, Javier A. ; Secrest, Roberta J. ; McNabb, Michelle ; Carranza-Lira, Sebastian ; Figueroa-Casas, Pedro ; Fernandes, César E. ; Romaguera, Josefina. / Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women. In: American Journal of Obstetrics and Gynecology. 2003 ; Vol. 188, No. 2. pp. 389-394.
@article{d2b45d5639034b06834fe53e00f8cb28,
title = "Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women",
abstract = "OBJECTIVE: The objectives were to evaluate mammographic changes in breast density that are associated with raloxifene or hormone therapy and to compare the safety profiles of the two therapies. STUDY DESIGN: Postmenopausal women older than 60 years who had a bone mineral density T-score of ≤-1 were assigned randomly to receive raloxifene hydrochloride 60 mg/day or continuous-combined hormone therapy that consisted of conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day in a 1-year, open-label study. Radiologists who were blinded to the treatment assignment assessed the mammograms according to the American College of Radiology Breast Image Reporting and Data System breast density categories. Breast density changes were analyzed for treatment differences. RESULTS: After 12 months of treatment, 0.9{\%} of the women who received raloxifene had increased mammographic breast density compared with 27.4{\%} of the women who received continuous-combined hormone therapy (P < .001). In the continuous-combined hormone therapy group, 77{\%} of the women reported breast tenderness at any time during the study, compared to 22{\%} of the women in the raloxifene group. CONCLUSION: In postmenopausal women with low bone mass, raloxifene therapy for 12 months does not increase mammographic breast density, whereas continuous-combined hormone therapy substantially increases breast density in a significant number of women.",
keywords = "Breast, Breast density, Breast tenderness, Continuous-combined hormone therapy, Raloxifene",
author = "Valerie Jackson and {San Martin}, {Javier A.} and Secrest, {Roberta J.} and Michelle McNabb and Sebastian Carranza-Lira and Pedro Figueroa-Casas and Fernandes, {C{\'e}sar E.} and Josefina Romaguera",
year = "2003",
month = "2",
day = "1",
doi = "10.1067/mob.2003.21",
language = "English",
volume = "188",
pages = "389--394",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women

AU - Jackson, Valerie

AU - San Martin, Javier A.

AU - Secrest, Roberta J.

AU - McNabb, Michelle

AU - Carranza-Lira, Sebastian

AU - Figueroa-Casas, Pedro

AU - Fernandes, César E.

AU - Romaguera, Josefina

PY - 2003/2/1

Y1 - 2003/2/1

N2 - OBJECTIVE: The objectives were to evaluate mammographic changes in breast density that are associated with raloxifene or hormone therapy and to compare the safety profiles of the two therapies. STUDY DESIGN: Postmenopausal women older than 60 years who had a bone mineral density T-score of ≤-1 were assigned randomly to receive raloxifene hydrochloride 60 mg/day or continuous-combined hormone therapy that consisted of conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day in a 1-year, open-label study. Radiologists who were blinded to the treatment assignment assessed the mammograms according to the American College of Radiology Breast Image Reporting and Data System breast density categories. Breast density changes were analyzed for treatment differences. RESULTS: After 12 months of treatment, 0.9% of the women who received raloxifene had increased mammographic breast density compared with 27.4% of the women who received continuous-combined hormone therapy (P < .001). In the continuous-combined hormone therapy group, 77% of the women reported breast tenderness at any time during the study, compared to 22% of the women in the raloxifene group. CONCLUSION: In postmenopausal women with low bone mass, raloxifene therapy for 12 months does not increase mammographic breast density, whereas continuous-combined hormone therapy substantially increases breast density in a significant number of women.

AB - OBJECTIVE: The objectives were to evaluate mammographic changes in breast density that are associated with raloxifene or hormone therapy and to compare the safety profiles of the two therapies. STUDY DESIGN: Postmenopausal women older than 60 years who had a bone mineral density T-score of ≤-1 were assigned randomly to receive raloxifene hydrochloride 60 mg/day or continuous-combined hormone therapy that consisted of conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day in a 1-year, open-label study. Radiologists who were blinded to the treatment assignment assessed the mammograms according to the American College of Radiology Breast Image Reporting and Data System breast density categories. Breast density changes were analyzed for treatment differences. RESULTS: After 12 months of treatment, 0.9% of the women who received raloxifene had increased mammographic breast density compared with 27.4% of the women who received continuous-combined hormone therapy (P < .001). In the continuous-combined hormone therapy group, 77% of the women reported breast tenderness at any time during the study, compared to 22% of the women in the raloxifene group. CONCLUSION: In postmenopausal women with low bone mass, raloxifene therapy for 12 months does not increase mammographic breast density, whereas continuous-combined hormone therapy substantially increases breast density in a significant number of women.

KW - Breast

KW - Breast density

KW - Breast tenderness

KW - Continuous-combined hormone therapy

KW - Raloxifene

UR - http://www.scopus.com/inward/record.url?scp=0037325121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037325121&partnerID=8YFLogxK

U2 - 10.1067/mob.2003.21

DO - 10.1067/mob.2003.21

M3 - Article

C2 - 12592245

AN - SCOPUS:0037325121

VL - 188

SP - 389

EP - 394

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -